New antiplatelet agents: Ticlopidine and clopidogrel. Antiplatelet therapy but at what cost?

Adverse Drug Reactions and Toxicological Reviews

Volumn 20, Issue 4, 2001, Pages 277-303

  Black, C ^a   Paterson, K R ^a  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ALLOPURINOL; ANTACID AGENT; ANTITHROMBOCYTIC AGENT; CHOLESTEROL; CLOPIDOGREL; DIPYRIDAMOLE; HEPARIN; INSULIN; PLACEBO; PYRIDINE DERIVATIVE; TICLOPIDINE; WARFARIN;

AGEUSIA; ARTERY THROMBOSIS; ARTHRITIS; BLEEDING; CLINICAL TRIAL; CORONARY ARTERY BYPASS SURGERY; CORONARY STENT; DIABETIC RETINOPATHY; DISORDERS OF CHOLESTEROL METABOLISM; DOSE RESPONSE; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG CLASSIFICATION; DRUG COST; DRUG EFFICACY; DRUG INFORMATION; DRUG MARKETING; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG SURVEILLANCE PROGRAM; DRUG TARGETING; FOOD DRUG INTERACTION; GASTROINTESTINAL SYMPTOM; HEMATOLOGIC DISEASE; HEPATITIS; HUMAN; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; META ANALYSIS; NONHUMAN; OUTCOMES RESEARCH; PERIPHERAL VASCULAR DISEASE; REVIEW; RISK BENEFIT ANALYSIS; SKIN DISEASE; STROKE; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE FUNCTION; THROMBOGENESIS;

ASPIRIN; BONE MARROW; HUMANS; PERIPHERAL VASCULAR DISEASES; PLATELET AGGREGATION INHIBITORS; THROMBOSIS; TICLOPIDINE;

EID: 0035199347     PISSN: 0964198X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (83)

1. Regular aspirin intake and acute myocardial infarction
2. Secondary prevention of vascular events by prolonged antiplatelet therapy
3. Collaborative overview of randomized trials of antiplatelet therapy. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
4. Dipyridamole
5. A secondary prevention, randomized control trial of suloctidil in patients with a recent history of thromboembolic stroke
6. Antiplatelet therapy with ticlopidine in unstable angina
7. Antiplatelet therapy
8. Disturbances of body fluids, haemostasis and flow of blood
9. Ticlopidine
10. Role of P2Y1 purinoceptor in ADP-induced platelet activation
11. Ticlopidine. An updated review of its pharmacology and theraputic use in platelet dependent disorders
12. The anti platelet effects of ticlopidine and clopidogrel
13. Ticlopidine and clopidogrel
14. Ticlopidine and antiplatelet therapy
15. Clopidogrel bioavailability: Absence of influence of food or antacids
16. Clopidogrel
17. Ticlopidine (hydrochoride)
18. A promise for the prevention and treatment of thrombosis and its complications
19. Pharmacokinetics of ticlopidine hydrochloride in young and old normal adult subjects following single and multiple dosing
20. 14C-Labeled Clopidogrel
21. Pharmacokinetics of clopidogrel
22. ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomized comparison of intravenous streptokinase, oral aspirin, both, or neither. The ISIS-2 (Second International Study of Infarct Survival) Collaborative Group
23. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)
24. Treatment and secondary prevention of stroke: Evidence, cost and effects on individuals and populations
25. Antiplatelet therapy for secondary stroke prevention
26. The Canadian American Ticlopidine Study (CATS) in Thromboembolic stroke
27. A critical appraisal of ticlopidine, a new antiplatelet agent
28. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high risk patients
29. Ticlopidine in the treatment of intermittent claudication: A 21-month double blind trial
30. Platelet inhibition with ticlopidine in atherosclerotic intermittent claudication
31. The STIMS trial: The ticlopidine experience and its clinical application. Swedish Ticlopidine Multicenter Study
32. Effect of ticlopidine on the long term patency of saphenous vein bypass grafts in the legs
33. Taming platelets in coronary stenting: Ticlopidine out, clopidogrel in?
34. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents
35. A clinical trial comparing three antithrombotic-drug regimens after coronary artery stenting
36. Safety and efficacy of ticlopidine for only 2 weeks after successful intracoronary stent placement
37. Antiplatelet rather than anticoagulant therapy with coronary stenting
38. Investigators for the CLASSICS Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary artery stenting: The Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS)
39. Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation
40. Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery
41. Choice of revascularization strategy for patients with coronary artery disease
42. Ticlopidine treatment reduces the progression of nonproliferative diabetic retinopathy
43. Effects of aspirin alone and aspirin plus dipyridamole in early diabetic retinopathy
44. Comparative safety and tolerability of clopidogrel and aspirin
45. Ticlopidine-induced colitis: A histopathological study including apoptosis
46. Platelet active drugs: The relationships among dose, effectiveness and side effects
47. Randomized trial of prophylactic daily aspirin in British male doctors
48. Final report on the aspirin component of the ongoing Physicians Health Study
49. Adverse haematological effects of ticlopidine
50. Safety and efficacy of ticlopidine for only 2 weeks after successful intracoronary stent placement
51. Ticlopidine-induced aplastic anemia and quick recovery with G-CSF: A case report and literature review
52. Ticlopidine-induced aplastic anemia: Development of chromosomal abnormalities and response to immuno-suppressive therapy
53. Ticlopidine associated aplastic anemia. A case report and review of the literature
54. CAPRIE trial
55. Fatal aplastic anaemia associated with clopidogrel
56. Clopidogrel and aplastic anaemia
57. Thrombotic thrombocytopenic purpura
58. High incidence of relapse in thrombotic thrombocytopenic purpura
59. Serious haematological reactions associated with ticlopidine - Update
60. Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting
61. Antibodies to von Willebrand factor cleaving protease in acute thrombotic thrombocytopenic purpura
62. Thrombotic thrombocytopenic purpura associated with clopidogrel
63. Increasing mortality from thrombotic thrombocytopenic purpura in the United States - Analysis of national mortality data
64. Influence on lipoprotein metabolism of the platelet inhibitory drug ticlopidine
65. Blood lipid profile in healthy subjects treated with ticlopidine
66. Comparison of ticlopidine and aspirin for the prevention of stroke
67. Comparison of ticlopidine and aspirin for the prevention of stroke
68. Cardiovascular and renal advisory panel of the FDA
69. Acute interstitial nephritis associated with ticlopidine
70. Ticlopidine and renal function
71. Ticlopidine and renal function
72. Ticlopidine and renal function
73. Ticlopidine and renal function
74. Clopidogrel and membranous nephropathy
75. Ticlopidine-induced cholestatic hepatitis: Report of three cases and review of the literature
76. Delayed onset ticlopidine-induced cholestatic jaundice
77. Ticlopidine-induced cholestatic jaundice
78. Cholestatic hepatitis due to ticlopidine: Clinical and histological recovery after drug withdrawal
79. Ticlopidine-induced prolonged cholestatis: A case report
80. Ticlopidine-induced-granulomatous hepatitis
81. Clopidogrel associated with acute arthritis
82. Reversible ageusia as an effect of clopidogrel treatment
83. The clopidogrel in unstable angina to prevent recurrent events (CURE) trial programme; Rationale, design and baseline characteristics including a meta-analysis of the effect of thienopyridines in vascular disease